Related Experiment Video
Updated: Aug 16, 2026

Chromatin Immunoprecipitation Assay Using Micrococcal Nucleases in Mammalian Cells
Published on: May 10, 2019
Decoy androgen-responsive element DNA can inhibit androgen receptor transactivation of the PSA promoter gene
Pengju Zhang1, Jianye Zhang, Charles Y F Young
1Institute of Biochemistry and Molecular Biology, School of Medicine, Shandong University, Jinan 250012, People's Republic of China.
Abstract:
Chemotherapy, hormonal therapy, or surgery may cause devastating toxic or other side effects. Androgen receptors (ARs) in the cytoplasm are activated by binding with androgen. Androgen-activated ARs bind to a specific genomic DNA sequence, the androgen-responsive element (ARE), and initiate gene expression at the transcriptional level. Even without androgen activation, ARs may have a role in androgen-refractory prostate cancer. Thus, inhibition of AR activity may have therapeutic value. We applied a genetic reporter of the Dual-Luciferase Assay System to test whether a short double-stranded genomic DNA containing prostate-specific antigen (PSA) ARE sequence as decoy DNA would inhibit the function of activated AR. A 21-mer phosphorothioated PSA ARE decoy DNA was synthesized, with a plasmid vector containing the PSA promoter upstream from a luciferase gene, the reporter gene. The promoter and reporter were co-transfected into a human prostate cancer cell line PC3-M with the aid of Lipofectamin 2000. After 24 hr exposure to androgens, the cells were lysed and luciferase activity measured to determine the ARE decoy inhibitory effect on the function of ARs. Luciferase activity was reduced significantly in the ARE decoy transfected cells but not with inactive control decoy. The results demonstrate that ARE decoy DNA can effectively suppress androgen-activated ARs in prostate cancer cells and indicate the potential utility of decoy DNA for developing a novel therapy for prostate cancer.
Insights
Decoy DNA targeting androgen receptors (ARs) effectively suppressed their activity in prostate cancer cells. This finding suggests a potential new therapeutic strategy for prostate cancer treatment.
Area of Science:
- Molecular Biology
- Genetics
- Oncology
Background:
- Androgen receptors (ARs) play a crucial role in prostate cancer progression.
- Current treatments like chemotherapy and hormonal therapy have significant side effects.
- Inhibiting AR activity presents a potential therapeutic avenue for prostate cancer.
Purpose of the Study:
- To investigate the efficacy of a prostate-specific antigen (PSA) androgen-responsive element (ARE) decoy DNA in inhibiting AR function.
- To assess the potential of decoy DNA as a novel therapeutic strategy for prostate cancer.
Main Methods:
- Utilized a Dual-Luciferase Assay System with a PSA ARE decoy DNA sequence.
- Co-transfected human prostate cancer cells (PC3-M) with a reporter plasmid (PSA promoter driving luciferase) and the decoy DNA.
- Measured luciferase activity after androgen exposure to determine the inhibitory effect of the ARE decoy.
Main Results:
- Significant reduction in luciferase activity was observed in cells transfected with the ARE decoy DNA.
- Control decoy DNA did not show a significant inhibitory effect.
- The results demonstrate that ARE decoy DNA effectively suppresses androgen-activated ARs in prostate cancer cells.
Conclusions:
- Androgen-responsive element decoy DNA can effectively inhibit androgen receptor activity in prostate cancer cells.
- Decoy DNA holds promise as a potential novel therapeutic approach for prostate cancer.
More Related Videos
13:19Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
09:07Detecting the Ligand-binding Domain Dimerization Activity of Estrogen Receptor Alpha Using the Mammalian Two-Hybrid Assay
Published on: December 19, 2018
Related Concept Videos
Co-activators and Co-repressors
RNA Polymerase II Accessory Proteins
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
Eukaryotic Transcription Activators
The binding domains are capable of recognizing and interacting with regulatory sequences on the DNA. These domains are...
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Internal Receptors